
    
      The primary objective of this study is to evaluate the plasma and urine PK of Levetiracetam
      (ucb L059) and its metabolite (ucb L057) after a single dose of LEV 250 mg or LEV 500 mg in
      Japanese subjects with normal renal function and in Japanese subjects with various degrees of
      renal impairment.
    
  